US-based science and tech services giant Danaher Corporation (NYSE: DHR) has announced a partnership between its subsidiary Beckman Coulter Laboratory Systems (Suzhou) Co., Ltd. and Huashan Hospital. The collaboration aims to develop innovative solutions for the early diagnosis and differential diagnosis of Alzheimer’s disease (AD). No financial details were disclosed.
First Danaher Beacon Science Research Program in China
This partnership marks the first Danaher Beacon science research cooperation program between Danaher and Chinese scientists. The collaboration will leverage Beckman Coulter’s high-sensitivity immunoassay platform and innovative detection technology to explore the potential association between blood biomarker combinations and clinical outcomes of Alzheimer’s disease and other neurodegenerative diseases.
Advancing Diagnostic Methods
The goal of the partnership is to promote the translational application of blood biomarkers in clinical practice and develop earlier and more accurate diagnostic methods for Alzheimer’s disease. The technology developed through this collaboration is also expected to be applicable to the diagnosis of other neurodegenerative and neuroimmune diseases, expanding the potential impact on patient care.-Fineline Info & Tech
Leave a Reply